Related Experiment Videos
Characterization of common BRCA1 and BRCA2 variants
Amie M Deffenbaugh1, Thomas S Frank, Michael Hoffman
1Myriad Genetic Laboratories, Salt Lake City, UT 84108, USA.
Genetic Testing
|September 7, 2002
Summary
This study analyzed common BRCA1 and BRCA2 gene variants to determine their clinical significance in hereditary breast and ovarian cancer risk. Eight common missense mutations were found to be non-deleterious, aiding in patient management.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Many missense variants in BRCA1 and BRCA2, key genes for hereditary breast and ovarian cancer, have unclear clinical significance.
- Accurate variant classification is crucial for patient management and genetic counseling.
Purpose of the Study:
- To characterize the clinical significance of eight common missense mutations in BRCA1 and BRCA2.
- To assess the impact of these variants on hereditary breast and ovarian cancer risk.
Main Methods:
- Analysis of variant prevalence in a control population.
- Examination of co-segregation with cancer within families.
- Evaluation of variant location, amino acid substitution, and conservation across species.
Main Results:
- BRCA1 variants R1347G, S1512I, and M1652I showed frequencies of 2.04%, 2.04%, and 4.08% respectively in controls.
- BRCA2 variants A2951T, V2728I, and D1420Y showed frequencies of 1.02%, 0.68%, and 0.34% respectively.
- BRCA2 variants T598A and R2034C were not observed in controls but are considered non-deleterious based on other data.
Conclusions:
- The BRCA1 missense mutations R1347G, S1512I, and M1652I are not deleterious.
- The BRCA2 missense mutations T598A, D1420Y, R2034C, V2728I, and A2951T are not deleterious.
- These findings clarify the significance of common BRCA variants, improving genetic risk assessment for breast and ovarian cancer.